Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/5/15  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Anthony Rosenberg

Wrong Anthony Rosenberg?

Managing Director

Phone: (617) ***-****  HQ Phone
Email: t***@***.com
Local Address:  United States
MPM Capital L.P.
The John Hancock Tower 200 Clarendon Street 54Th Floor
Boston , Massachusetts 02116
United States

Company Description: MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • Masters of Science , Physiology
    University of London
  • Bachelor of Science degree , Biological Sciences
    University of Leicester
  • BSc
86 Total References
Web References
Anthony ...
www.bioexecinstitute.org, 5 Oct 2015 [cached]
Anthony Rosenberg
...
Anthony Rosenberg
Managing Director, MPM Capital
Tony ...
www.radiuspharm.com, 18 Oct 2015 [cached]
Tony Rosenberg
...
Tony Rosenberg is retired from Novartis where he was Head of M&A and Licensing. Most recently he was responsible for the Portfolio Transformation transactions undertaken by Novartis, which are seen as landmark deals in the industry.
Tony joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing (Pharma) and has managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestment and M&A deals. In 2010 he was given additional responsibility for leadership of the Molecular Diagnostics group. In 2013 he was appointed as Head M&A and Licensing (Corporate).
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
Radius Health Appoints Former ...
ir.radiuspharm.com, 2 Mar 2015 [cached]
Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors | Previous Release Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors (NASDAQ:RDUS)
...
Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors
WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today the appointment of Tony Rosenberg to its Board of Directors. Mr. Rosenberg had a long and successful career at Novartis, most recently serving as Corporate Head of M&A and Licensing for all of Novartis. He previously held various general management and executive leadership positions, including roles in business development, strategic planning, and marketing and sales.
...
"Our Board and management team are thrilled to have Tony become the newest member of the Board as we work together to guide and shape future success."
Tony Rosenberg will also be taking the role of Chair of the Strategy Committee, replacing Dr. Morana Jovan, who resigned from the Radius Board.
...
Tony Rosenberg first joined Sandoz in the UK in1980 where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994, he moved to Basel, initially in international product marketing, and after undertaking roles of increasing responsibility, he was named Head Global Marketing Primary Care. In 2000, Tony was named Global Head of the Transplant and Immunology Business Unit, and in 2005 he was appointed Global Head Business Development & Licensing (Pharma). In this role, Tony managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestitures, mergers, and acquisitions. In 2013, he was appointed as Corporate Head of M&A and Licensing. Most recently, Tony was responsible for the Portfolio Transformation transactions undertaken by Novartis. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
The current Class I Directors are ...
ir.radiuspharm.com, 18 Oct 2015 [cached]
The current Class I Directors are Owen Hughes, Elizabeth Stoner, M.D. and Robert E. Ward; the current Class II Directors are Alan H. Auerbach, Ansbert K. Gadicke, M.D. and Martin Münchbach, Ph.D; and the current Class III Directors are Willard H. Dere, M.D., Kurt C. Graves and Anthony Rosenberg.
...
Anthony Rosenberg
...
ANTHONY ROSENBERG
...
Anthony Rosenberg has served on our Board of Directors since March 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from
...
Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector.
...
Our Board of Directors currently consists of nine (9) members: Alan H. Auerbach, Willard H. Dere, M.D., Ansbert K. Gadicke, M.D., Kurt C. Graves, Owen Hughes, Martin Münchbach, Ph.D., Anthony Rosenberg, Elizabeth Stoner, M.D. and Robert E. Ward.
...
Our Board of Directors has affirmatively determined that each of Alan H. Auerbach, Willard H. Dere, M.D., Ansbert K. Gadicke, M.D., Kurt C. Graves, Owen Hughes, Martin Münchbach, Ph.D., Anthony Rosenberg and Elizabeth Stoner, M.D. is an "independent director," as defined under NASDAQ rules.
...
Anthony Rosenberg
Tony ...
www.bioexecinstitute.org, 19 Nov 2014 [cached]
Tony Rosenberg
...
Anthony Rosenberg
Head, Partnering & Emerging Businesses
Other People with the name "Rosenberg":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304